institute of virology (viro)

Font size »A . A+ . A++ .

Viral vectors and vaccines

Viral vector vaccines
(Priv. Doz. Dr. Ingo Drexler)

Selected Publications

  • Nörder, M., Becker, P.D., Drexler, I., Link, C., Erfle, V., and Guzmán, C. A.  (2010) Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model. PLoSONE Jun 30; 5(6):e11400.
  • Huster, K.M., Stemberger, C., Gasteiger, G., Kastenmüller, W., Drexler, I., and Busch, D.H. (2009). Memory CD8 T cell compartment grows in size with immunological experience but nevertheless can lose function. J Immunol. 183, 6898-6902
  • Kastenmuller, W., Gasteiger, G., Stross, L., Busch, D.H., and Drexler I. (2009) Mucosal application of a lyophilized viral vector vaccine confers systemic and protective immunity towards intracellular pathogens. J Immunol 182, 2573-2257.
  • Ohnmacht, C., Pullner, A., King, S.B.S., Drexler, I., Meier, S., Brocker, T., and Vöhringer, D. (2009) Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med 206, 549-559
  • Meyer, V. S., Kastenmüller, K., Gasteiger, G., Franz-Wachtel, M., Lamkemeyer, T., Rammensee, H.G., Stevanovic, S., Sigurdardottir, D., and Drexler, I. (2008) Long-term immunity against actual poxviral HLA ligands as identified by differential stable isotope labeling. J Immunol 181, 6371-6383.

  • Gasteiger, G., Kastenmuller, W., Ljapoci, R., Sutter, G., and Drexler, I. (2007) Cross-priming of cytotoxic T-cells dictates antigen requisites for MVA vector vaccines. J Virol 81, 11925-11936.
  • Kastenmuller, W., Gasteiger, G., Gronau, J., Baier, R., Ljapoci, R., Busch, D.H. and Drexler, I. (2007) Cross- competition of CD8+ T-cells shapes the immuno-dominance hierarchy during boost vaccination. J Exp Med 204, 2187-2198.
  • Kastenmuller, W.*, Drexler, I.*, Ludwig, H., Erfle, V., Peschel, C., Bernhard, H., and Sutter,G. (2006) Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. Virology 350, 276-288. (*equal contribution)
  • Drexler, I., Staib, C., and Sutter, G. (2004) Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 15, 506-512.
  • Drexler, I., Staib, C., Kastenmuller, W., Stefanovitc, S., Schmidt, B., Lemonnier, F.A., Rammensee, H.G., Busch, D.H., Bernhard, H., Erfle, V., and Sutter, G. (2003) Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T-cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci USA 100, 217-222.
  • Drexler, I., Antunes, E., Schnitz, M., Wölfel, T., Huber, C., Erfle, V., Rieber, P., Theobald, M., and Sutter, G. (1999) Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukoxyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res 59, 4955-4963.

 

Selected Patents

  • Drexler, I., Erfle, V., Sutter, G., Recombinant MVA expressing the HER-2/neu gene. Granted for Europe
    (EP 1188834 / 30.08.01; 20.03.05).
  • Drexler, I., Sutter, G., Gasteiger, G., Erfle, V., Vaccines based on the use of MVA. Pending forEurope
    (EP 1851320 / 24.01.06), Canada (CA 2595629 / 24.01.06), USA (US / 24.07.07), Japan (JP / 24.01.06), China (CN / 24.01.06) and India (IN / 24.01.06).
  • Drexler, I., Erfle, V., Guzmann, C., Becker, P., Nörder, M., Use of MVA as adjuvant in the stimulation of APC’s. Pending for Europe (EP 06121795.6 / 05.10.06) and International (WO / 05.10.07).
  • Drexler, I., Kastenmuller, W., Gasteiger, G., Guzmann, C., Becker, C., Nörder, M., VV promoter-driven overexpression of recombinant antigens. Pending for Europe (EP).